(RTTNews) - Centessa Pharmaceuticals plc (CNTA) has priced its underwritten public offering of 11.63 million American Depositary Shares ("ADSs"), each representing one ordinary share, at $21.50 per ADS.
This clinical-stage biopharmaceutical company is pioneering a new class of therapies targeting orexin receptor 2 (OX2R) for neurological, neurodegenerative, and neuropsychiatric disorders.
The offering, which is scheduled to close on or about November 14, 2025, is expected to generate gross proceeds of approximately $250 million before deducting underwriting discounts and expenses.
The underwriters have a 30-day option to purchase up to an additional 1.74 million ADSs at the public offering price, less underwriting discounts and commissions.
CNTA has traded in the range of $9.60 - $25.42 in the last 1 year. The stock closed yesterday's trading at $22.54, up 0.94%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
